AbbVie to Acquire Capstan Therapeutics for $2.1 Billion to Boost In Vivo CAR-T Portfolio

Pending Hart-Scott-Rodino approval, AbbVie will integrate Capstan’s Phase 1 CAR-T candidate with its targeted lipid nanoparticle platform for precise RNA delivery.